CVS to Cover Lilly's GLP-1 Drugs, Expanding Access to Millions of Americans
📊 LLY — Piyasa Yorumu
▲ up · 65%The news highlights the potential for increased demand for LLY's GLP-1 drugs following their inclusion in CVS's coverage. Technical indicators confirm a strong uptrend: the RSI is approaching overbought territory at 69 but maintains momentum, while the MACD remains above its signal line and positive. The price is trading above both the 20-day and 50-day moving averages, having gained over 6% in the last 24 hours. The upward trend is expected to continue in the short term, though caution is warranted for a potential pullback as the RSI nears overbought levels.
📊 CVS — Piyasa Yorumu
▲ up · 65%The news indicates that CVS's inclusion of popular GLP-1 drugs in its coverage could bring a significant demand increase to the company's healthcare segment. Technically, the RSI at 51 is in neutral territory, while the MACD is close to crossing above the signal line, which could be a short-term bullish signal. The price closed above the 20-day moving average (91.89), with potential for a move toward the 50-day average (93.19). However, the slight decline in the latest close and overall market uncertainty limit the bullish outlook to moderate confidence.